Overview

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

Status:
Completed
Trial end date:
2007-05-09
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25 otherwise healthy adult patients with onychomycosis.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Tavaborole